Leading trustworthy AI in life sciences

Artificial intelligence (AI) is disrupting the pharmaceutical industry, promising considerable time and cost savings, from research to bringing new drugs to market

However, its adoption raises crucial questions about model safety, robustness, ethics, and regulatory compliance. In response to these challenges, the concept of “trustworthy AI” is emerging as a necessity to ensure the responsible development and use of this technology.

To address these challenges, the European AI Act introduces a series of new requirements aimed at ensuring the safety of people and property. It also encourages innovation around testing techniques to better manage bias and other risks associated with AI development. Moreover, this legislative text also provides for enhanced technical documentation to enable compliance assessment on multiple aspects, such as robustness, transparency, and performance monitoring of developed AI systems, including post-deployment. Similar trends are emerging globally, with specific adaptations to the pharmaceutical and life sciences industries at national and regional levels.

Capgemini has taken the lead in this transition by anticipating these regulatory aspects and closely collaborating with our clients to develop a platform compliant with the future European AI legislation. By incorporating an approach specifically tailored to the regulated life sciences sector, we ensure that its solutions comply not only with general AI requirements, but also with the rigorous standards and best practices specific to this industry.

Part 1 of this two-part series explores the leadership required to integrate, master, and comply with trusted AI in the life sciences. Part two will discuss recommendations and best practices for deploying trusted AI in this field.